Health News

The New York Times: A Food and Drug Administration advisory panel Thursday recommended that the agency approve “a medicine that could help prevent pregnancy if taken as late as five days after unprotected sex. The pill, called ella, sprang from government labs and appears to be more effective than Plan B, a morning-after pill now available over the counter to women 18 and older that gradually loses efficacy after intercourse and can be taken at latest three days after sex.

Read more

Filed under: Pharmacy News
Tags: Drug, medicine, Pharmacy, Pregnancy, Sex

Related posts

• New study: Men who consume hair loss drug may report sexual dysfunction (0)
  A new study by The George Washington University School of Medicine and Health Sciences, that will be published in the Journal of Sexual Medicine, suggests men who take the drug finasteride, commonly marketed under the trademark names Propecia and Proscar, may report an on-going reduction in sex drive, and in some cases, prolonged periods of [...]
  
  
• Fake Morning After Pill Maybe In U.S. FDA Warns Public; Stay Protected (0)
  There is a fake "morning after" pill on the market and the U.S. Food and Drug Administration (FDA) is warning the public about it. The drug's name is called Evital and no such product has been approved to date and it may not be safe or effective in preventing pregnancy although approved in South [...]
  
  
• Days-After Pill Wins FDA Approval (0)
  (MedPage Today) -- The emergency contraceptive drug ulipristal acetate (ella) can be marketed in the U.S. for preventing pregnancy up to five days after unprotected sex, the FDA said. Read more [tags] Pharmacy News [/tags]
  
  
• Advisory Panel Recommends FDA Approve New "Morning After" Pill (0)
  The New York Times: A Food and Drug Administration advisory panel Thursday recommended that the agency approve "a medicine that could help prevent pregnancy if taken as late as five days after unprotected sex... Read more [tags] Women's Health [/tags]
  
  
• Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine (0)
  Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma [...]